Analysis of genetic biomarkers, polymorphisms in ADME-related genes and their impact on pharmacotherapy for prostate cancer

Cancer Cell International

Review

Liang Yujie¹  Hina Ayub²  Naseem Saba²  Deng Zhiqin³  Zoya Iqbal³  Li Duan³  Khurram Rehman⁴  Muzammil Ahamd Khan⁵ 

[1] Department of Child and Adolescent Psychiatry, Shenzhen Kangning Hospital, Shenzhen Mental Health Center, 518035, Shenzhen, Guangdong, China;Department of Gynae, Gomal Medical College, D.I.Khan, Pakistan;Department of Orthopedics, The First Affiliated Hospital of Shenzhen University, Second People’s Hospital, 518035, ShenzhenShenzhen, Guangdong, China;Guangdong Provincial Research Center for Artificial Intelligence and Digital Orthopedic Technology, Shenzhen Second People’s Hospital, 518035, Shenzhen, Guangdong, China;Faculty of Pharmacy, Gomal University, D.I.Khan, Pakistan;Institute of Biochemistry and Biotechnology, D.I.Khan, Pakistan;

关键词: SNPs;    Androgen metabolism;    Pharmacotherapy;    Biomarkers;    Prostate cancer;    Genetic polymorphism;   

DOI  :  10.1186/s12935-023-03084-5

 received in 2023-02-23, accepted in 2023-09-24,  发布年份 2023

来源: Springer

【 摘 要 】

Prostate cancer (PCa) is a non-cutaneous malignancy in males with wide variation in incidence rates across the globe. It is the second most reported cause of cancer death. Its etiology may have been linked to genetic polymorphisms, which are not only dominating cause of malignancy casualties but also exerts significant effects on pharmacotherapy outcomes. Although many therapeutic options are available, but suitable candidates identified by useful biomarkers can exhibit maximum therapeutic efficacy. The single-nucleotide polymorphisms (SNPs) reported in androgen receptor signaling genes influence the effectiveness of androgen receptor pathway inhibitors and androgen deprivation therapy. Furthermore, SNPs located in genes involved in transport, drug metabolism, and efflux pumps also influence the efficacy of pharmacotherapy. Hence, SNPs biomarkers provide the basis for individualized pharmacotherapy. The pharmacotherapeutic options for PCa include hormonal therapy, chemotherapy (Docetaxel, Mitoxantrone, Cabazitaxel, and Estramustine, etc.), and radiotherapy. Here, we overview the impact of SNPs reported in various genes on the pharmacotherapy for PCa and evaluate current genetic biomarkers with an emphasis on early diagnosis and individualized treatment strategy in PCa.

【 授权许可】

CC BY   
© BioMed Central Ltd., part of Springer Nature 2023

【 图 表 】

Fig. 4

Fig. 2

Scheme 1